M1 muscarinic receptor selective antagonist. Inverse agonist activity reported.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 424.33. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.36 mL||11.78 mL||23.57 mL|
|5 mM||0.47 mL||2.36 mL||4.71 mL|
|10 mM||0.24 mL||1.18 mL||2.36 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Daeffler et al (1999) Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors. Br.J.Pharmacol. 126 1246 PMID: 10205015
Doods et al (1994) Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur.J.Pharmacol. 253 275 PMID: 8200421
Eglen et al (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol.Rev. 48 531 PMID: 8981565
Hammer et al (1980) Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283 90 PMID: 7350532
If you know of a relevant reference for Pirenzepine dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: Pirenzepine dihydrochloride, supplier, Selective, M1, muscarinic, antagonists, Receptors, Acetylcholine, ACh, M1, Receptors, Tocris Bioscience
10 Citations for Pirenzepine dihydrochloride
Citations are publications that use Tocris products. Selected citations for Pirenzepine dihydrochloride include:
Buchanan et al (2010) Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels. Neuron 68 948 PMID: 21145007
Nadal et al (2016) Presynaptic muscarinic acetylcholine autoreceptors (M1, M2 and M4 subtypes), adenosine receptors (A1 and A2A) and tropomyosin-related kinase B receptor (TrkB) modulate the developmental synapse elimination process at the neuromuscular junction. Front Cell Neurosci 9 67 PMID: 27339059
Ahmed (2016) Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. Physiological Reports 4 e13069 PMID: 28039410
Pediani et al (2016) Dynamic regulation of quaternary organization of the M1 muscarinic receptor by subtype-selective antagonist drugs. J.Biol.Chem. 291 13132 PMID: 27080256
Tian et al (2016) STEP activation by Gαq coupled GPCRs opposes Src regulation of NMDA receptors containing the GluN2A subunit Scientific Reports 6 36684 PMID: 27857196
Tozzi et al (2015) Endogenous 17β-estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. Front Cell Neurosci 9 192 PMID: 26074768
Martin et al (2015) Endocannabinoids Mediate Muscarinic Acetylcholine Receptor-Dependent Long-Term Depression in the Adult Medial Prefrontal Cortex. Proc Natl Acad Sci U S A 9 457 PMID: 26648844
Pacini et al (2014) M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biol Ther 15 1489 PMID: 25482946
Mans et al (2014) An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3-CA1 synapses in the hippocampus of adult rats. J Neurophysiol 112 2388 PMID: 25143547
Tozzi et al (2012) A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation. PLoS One 7 e38312 PMID: 22715379
Do you know of a great paper that uses Pirenzepine dihydrochloride from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.